Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026)
Johnson & Johnson (JNJ) posted Goodwill & Intangibles of $96.7 billion for Q2 2026, down 0.93% sequentially from $97.6 billion in Q1 2026, and down 1.27% YoY from $98.0 billion in Q2 2025.
Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Goodwill & Intangibles for 18 years, with the latest figure at $96.7 billion in Q2 2026.
- Quarterly Goodwill & Intangibles fell 1.27% year-over-year to $96.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $96.7 billion (down 1.27% YoY) and the FY2025 annual result came in at $99.2 billion, up 21.21% from the prior year.
- Goodwill & Intangibles fell to $96.7 billion in Q2 2026 per JNJ's latest filing, from $97.6 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $99.2 billion in Q4 2025 and troughed at $70.7 billion in Q4 2023.
- A 5-year average of $83.8 billion and a median of $81.8 billion in 2024 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2022 and 2024: Goodwill & Intangibles surged 54.66% in 2022, then retreated 23.78% in 2024.
- Over 5 years, Goodwill & Intangibles stood at $73.7 billion in 2022, then slipped by 4.05% to $70.7 billion in 2023, then grew by 15.67% to $81.8 billion in 2024, then increased by 21.21% to $99.2 billion in 2025, then decreased by 2.49% to $96.7 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $96.7 billion, $97.6 billion, and $99.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 96.71 Bn |
| Mar 29, 2026 | 97.62 Bn |
| Dec 28, 2025 | 99.18 Bn |
| Sep 28, 2025 | 96.79 Bn |
| Jun 29, 2025 | 97.95 Bn |
| Mar 30, 2025 | 81.22 Bn |
| Dec 29, 2024 | 81.82 Bn |
| Sep 29, 2024 | 84.29 Bn |
| Jun 30, 2024 | 83.98 Bn |
| Mar 31, 2024 | 70.90 Bn |
| Dec 31, 2023 | 70.73 Bn |
| Oct 1, 2023 | 71.15 Bn |
| Jul 2, 2023 | 91.69 Bn |
| Apr 2, 2023 | 93.02 Bn |
| Jan 1, 2023 | 74.54 Bn |
| Oct 2, 2022 | 73.72 Bn |
| Jul 3, 2022 | 76.57 Bn |
| Apr 3, 2022 | 79.36 Bn |
| Jan 2, 2022 | 71.83 Bn |
| Oct 3, 2021 | 83.35 Bn |